Acute ischemic stroke
Conditions
Interventions
Intervention group :hyperbaric oxygen therapy+edaravone dexborneol
Control group:edaravone dexborneol
Sponsors
Jingzhou central hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Age = 18 years old; 2) Clinically diagnosed with acute cerebral infarction; Patients must meet diagnostic criteria for acute ischaemic stroke, such as those based on imaging findings such as CT or MRI of the brain. 3) have been informed of the content of the informed consent form and agree to participate; 4) The time from the onset of the stroke to the time of admission =48 hours, if the exact time of onset is unknown, the time of onset of the patient is defined as "the time when the patient last appeared to be normal"; 5) mRS = 1 point before onset; 6) 25=NIHSS=5. 7) The administration time of edaravone dexterpresanol injection should be within 48 hours after the onset of AIS; Note: Time of onset is defined as the point in time when symptoms first appear; For ischaemic stroke occurring in sleep, onset is defined as the point in time at which the patient last observed normality or the latest point in time when the patient self-reported normal. 8) cerebral magnetic resonance imaging (MRI) confirmed cerebral cortical hemisphere infarction (anterior circulation), including diffusion-weighted imaging; 9) Able to receive hyperbaric oxygen therapy within 48 hours.
Exclusion criteria
Exclusion criteria: 1. Low level of consciousness (NIHSS 1a 3 points); 2. MRI or CT showed clinically significant haemorrhagic outcomes; Acute intracranial haemorrhagic disorders confirmed by imaging: parenchymal haemorrhage, epidural haematoma, subdural haematoma, ventricular haemorrhage, subarachnoid haemorrhage, etc.; 3. Ipsilateral focal neurological deficits due to a previous brain lesion would complicate the evaluation; 4. Post-ischaemic stroke seizures; 5. History of neurological events, such as stroke or clinically significant head trauma, within 6 months prior to the start of screening; 6. Hypertension that is refractory to control despite hypotensive therapy, defined as sustained systolic blood pressure > 220 mmHg or diastolic blood pressure > 120 mmHg; 7. Baseline blood glucose level 350mg/dL; 8. Patients with severe comorbidities, including but not limited to: A. Severe renal disease requiring haemodialysis or peritoneal dialysis; B. Advanced liver disease, such as hepatitis or cirrhosis; C. Severe congestive heart failure or ejection fraction <30%; D. Severe lung disease requiring oxygen at home; E. Active unstable angina requiring daily nitrate or other medication; 9. Known human immunodeficiency virus infection, ongoing systemic infection, severe local infection or immunocompromised; 10. Alzheimer's disease or other dementia, Parkinson's disease, or any other neurological disease that, in the opinion of the trial physician, would affect its ability to participate in the trial or confound the study evaluation; 11. History of malignant tumour within 2 years after the onset of ischaemic stroke, except for basal cell carcinoma or squamous cell carcinoma of the skin that has been appropriately treated; 12. Contraindications to MRI, such as implantation of pacemakers or other metal prostheses incompatible with MRI, weight or claustrophobia. 13. Other serious medical or psychiatric illness, not under adequate control, and which, in the opinion of the investigator, does not allow the subject to be managed in accordance with the protocol; 14. Large fluctuations in the state of the nervous system after the onset of ischaemic stroke, indicating the progression or expansion of ischaemic stroke, or the possibility of transient ischaemic attack; 15. Neurovascular surgery (such as carotid endarterectomy, stenting, etc.) planned within one year after ischaemic stroke; 16. Abnormal laboratory test results that are considered clinically significant and not suitable for the trial by the investigator. 17. Patients who are pregnant or lactating and who are planning to become pregnant within 90 days; 18. Patients with severe renal failure (eGFR < 30ml/min); 19. Patients with concurrent malignant tumours or severe systemic diseases with an expected survival time of less than 90 days; 20. Patients with severe mental disorders or unable to cooperate with the completion of informed consent and follow-up due to dementia; 21. Life expectancy is less than 1 year; 22. Indications for systemic infection; 23. Suspicion of aortic dissection, suspected septic emboli, or bacterial endocarditis; 24. The neurologist believes that the cause of cerebral embolism has been identified or other special circumstances are not suitable to participate in this study; 25. Patients who, in the opinion of the investigator, are not suitable to participate in the study.26. Have received emergency thrombectomy or anticipate the need for elective cerebrovascular balloon dilation a
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| National Institute of Health stroke scale ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Modified Rankin Scale ; | — |
Countries
china
Contacts
Public ContactSujunfeng
Jingzhou central hospital
Outcome results
None listed